Literature DB >> 35772041

Modern Myeloma Therapy + Sustained Minimal Residual Disease-Negative = (Functional) Cure!

Ola Landgren1, Dickran Kazandjian1.   

Abstract

Entities:  

Mesh:

Year:  2022        PMID: 35772041      PMCID: PMC9426854          DOI: 10.1200/JCO.22.00622

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   50.717


× No keyword cloud information.
  18 in total

1.  Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.

Authors:  Peter M Voorhees; Jonathan L Kaufman; Jacob Laubach; Douglas W Sborov; Brandi Reeves; Cesar Rodriguez; Ajai Chari; Rebecca Silbermann; Luciano J Costa; Larry D Anderson; Nitya Nathwani; Nina Shah; Yvonne A Efebera; Sarah A Holstein; Caitlin Costello; Andrzej Jakubowiak; Tanya M Wildes; Robert Z Orlowski; Kenneth H Shain; Andrew J Cowan; Sean Murphy; Yana Lutska; Huiling Pei; Jon Ukropec; Jessica Vermeulen; Carla de Boer; Daniela Hoehn; Thomas S Lin; Paul G Richardson
Journal:  Blood       Date:  2020-08-20       Impact factor: 22.113

Review 2.  A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival.

Authors:  Dickran Kazandjian; Ola Landgren
Journal:  Semin Oncol       Date:  2016-11-16       Impact factor: 4.929

3.  MRD-driven treatment paradigm for newly diagnosed transplant eligible multiple myeloma patients.

Authors:  O Landgren; S Giralt
Journal:  Bone Marrow Transplant       Date:  2016-02-29       Impact factor: 5.483

4.  Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.

Authors:  Michel Attal; Valerie Lauwers-Cances; Cyrille Hulin; Xavier Leleu; Denis Caillot; Martine Escoffre; Bertrand Arnulf; Margaret Macro; Karim Belhadj; Laurent Garderet; Murielle Roussel; Catherine Payen; Claire Mathiot; Jean P Fermand; Nathalie Meuleman; Sandrine Rollet; Michelle E Maglio; Andrea A Zeytoonjian; Edie A Weller; Nikhil Munshi; Kenneth C Anderson; Paul G Richardson; Thierry Facon; Hervé Avet-Loiseau; Jean-Luc Harousseau; Philippe Moreau
Journal:  N Engl J Med       Date:  2017-04-06       Impact factor: 91.245

5.  NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022.

Authors:  Natalie S Callander; Muhamed Baljevic; Kehinde Adekola; Larry D Anderson; Erica Campagnaro; Jorge J Castillo; Caitlin Costello; Srinivas Devarakonda; Noura Elsedawy; Matthew Faiman; Alfred Garfall; Kelly Godby; Jens Hillengass; Leona Holmberg; Myo Htut; Carol Ann Huff; Malin Hultcrantz; Yubin Kang; Sarah Larson; Michaela Liedtke; Thomas Martin; James Omel; Douglas Sborov; Kenneth Shain; Keith Stockerl-Goldstein; Donna Weber; Ryan A Berardi; Rashmi Kumar; Shaji K Kumar
Journal:  J Natl Compr Canc Netw       Date:  2022-01       Impact factor: 11.908

6.  Early versus late response to daratumumab-based triplet therapies in patients with multiple myeloma: a pooled analysis of trials POLLUX, CASTOR and MAIA.

Authors:  Jiasheng Wang; Raul Arroyo-Suarez; Srilatha Dasari; Kanithra Sekaran; William Tse
Journal:  Leuk Lymphoma       Date:  2022-02-10

7.  Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.

Authors:  Nikhil C Munshi; Herve Avet-Loiseau; Andy C Rawstron; Roger G Owen; J Anthony Child; Anjan Thakurta; Paul Sherrington; Mehmet Kemal Samur; Anna Georgieva; Kenneth C Anderson; Walter M Gregory
Journal:  JAMA Oncol       Date:  2017-01-01       Impact factor: 31.777

8.  Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis.

Authors:  O Landgren; S Devlin; M Boulad; S Mailankody
Journal:  Bone Marrow Transplant       Date:  2016-09-05       Impact factor: 5.483

9.  Timing the initiation of multiple myeloma.

Authors:  Even H Rustad; Venkata Yellapantula; Daniel Leongamornlert; Niccolò Bolli; Guy Ledergor; Ferran Nadeu; Nicos Angelopoulos; Kevin J Dawson; Thomas J Mitchell; Robert J Osborne; Bachisio Ziccheddu; Cristiana Carniti; Vittorio Montefusco; Paolo Corradini; Kenneth C Anderson; Philippe Moreau; Elli Papaemmanuil; Ludmil B Alexandrov; Xose S Puente; Elias Campo; Reiner Siebert; Herve Avet-Loiseau; Ola Landgren; Nikhil Munshi; Peter J Campbell; Francesco Maura
Journal:  Nat Commun       Date:  2020-04-21       Impact factor: 14.919

10.  Revealing the impact of structural variants in multiple myeloma.

Authors:  Ola Landgren; Francesco Maura; Even H Rustad; Venkata D Yellapantula; Dominik Glodzik; Kylee H Maclachlan; Benjamin Diamond; Eileen M Boyle; Cody Ashby; Patrick Blaney; Gunes Gundem; Malin Hultcrantz; Daniel Leongamornlert; Nicos Angelopoulos; Luca Agnelli; Daniel Auclair; Yanming Zhang; Ahmet Dogan; Niccolò Bolli; Elli Papaemmanuil; Kenneth C Anderson; Philippe Moreau; Hervé Avet-Loiseau; Nikhil C Munshi; Jonathan J Keats; Peter J Campbell; Gareth J Morgan
Journal:  Blood Cancer Discov       Date:  2020-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.